In an era increasingly shaped by the transformative power of artificial intelligence, a Los Angeles-based telehealth startup, MEDVi, has captured…
Read More
Top Automated Dispensing Cabinets for Pharmacies: Leading Brands Compared
The imperative to streamline workflows and enhance patient safety has propelled automated medication distribution to the forefront of modern pharmacy…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders
OrsoBio, a specialized biotechnology company strategically focused on addressing obesity and its myriad related metabolic dysfunctions, is charting a course…
Read More
Sai Life Sciences Plans to Recruit 700+ Professionals in FY27 as Indian CRDMO Demand Accelerates
Sai Life Sciences, a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in Hyderabad, India, has announced an ambitious…
Read More
Eli Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial, revealing that its investigational triple agonist,…
Read More
Novo Nordisk’s New Weight Loss Treatment CagriSema Shows Inferiority to Lilly’s Tirzepatide in Head-to-Head Trial
Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its eagerly anticipated weight loss treatment,…
Read More
Eli Lilly Ascends to Pharmaceutical Revenue Zenith with Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced
Indianapolis, IN – Eli Lilly and Company, a venerable pharmaceutical giant, has officially seized the top position in global pharmaceutical…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, recently announced compelling Phase 2 trial results for its investigational…
Read More
Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025
Eli Lilly and Company has officially ascended to the pinnacle of the global pharmaceutical industry, concluding fiscal year 2025 as…
Read More
Engineered exosomes from pig semen: a high-yield platform for non-invasive ocular drug delivery
In a groundbreaking development that could revolutionize the treatment of ocular cancers, researchers in China have successfully engineered eye drops…
Read More
